When “Mild” Tardive Dyskinesia Isn’t Mild to the Patient

The Psychiatric Record | Clinical Assessment | Monday, October 5, 2026

Calling tardive dyskinesia mild can end a conversation that has barely started. The description may accurately capture the movements observed during an examination. It does not tell us what the person has stopped doing because of them.

The treatment discussion needs both accounts: what the clinician observes and what the patient experiences. Otherwise, a decision to monitor can quietly become a decision to tolerate a burden that was never explored.

This matters particularly when psychiatric treatment has otherwise helped. A patient should be able to describe unwanted movements without having that conversation reduced to a choice between accepting them and losing an effective antipsychotic.

The American Psychiatric Association's schizophrenia guideline recommends a reversible VMAT2 inhibitor for antipsychotic-associated tardive dyskinesia that is moderate to severe or disabling. Its implementation discussion also allows consideration in mild TD when preference, impairment or psychosocial effects justify it. These are different levels of recommendation, not a mandate to medicate every movement.

The same guideline cautions that an AIMS or DISCUS total has no fixed intervention threshold. Identical totals can represent different manifestations and burdens. Assessment must also address other possible causes of abnormal movements. A concerning examination does not establish the explanation by itself.

Disability is part of the treatment question. Waiting for movements to look more dramatic can miss the reason a patient wants help now.

A 2021 consensus paper by Jackson and colleagues offers a useful way to organize that conversation: explore physical, social, vocational and psychological effects, along with effects on psychiatric care. The authors describe difficulties involving eating, speech and hand use, as well as embarrassment and withdrawal. They recommend asking directly rather than relying on volunteered complaints. When awareness of the movements is limited, they also recommend input from caregivers, family or friends.

This was expert consensus, not a trial showing that an interview strategy improves outcomes. Teva funded the meetings and manuscript support; the authors reported that the sponsor did not participate in developing the recommendations or manuscript. Those limits matter when weighing the paper's advice.

The domains are most useful when they lead to a concrete account. Instead of stopping at “bothersome,” ask the patient to describe what has changed during a meal, a conversation or a usual task. Which problem would they most want treatment to improve? What do they still do, but with effort or avoidance that would otherwise go unnoticed?

AIMS itself includes global items concerning incapacitation and awareness or distress, as the consensus paper notes. The failure is not that the instrument has no room for impact. It is allowing a total in the record to stand in for a conversation that never happened.

A treatment plan must account for the condition the antipsychotic is treating. The APA guideline notes that tardive movements can persist or worsen after reduction or discontinuation. The guideline generally favors valbenazine or deutetrabenazine over tetrabenazine because their supporting evidence is stronger.

Those recommendations do not remove the need for current, product-specific safety review. For example, the April 2026 valbenazine label includes warnings about sedation, QT prolongation and parkinsonism. Its boxed warning and section 5.1 address depression and suicidality in Huntington's disease. The TD trial described in section 14.1 excluded patients at significant risk for suicidal or violent behavior and those with unstable psychiatric symptoms, so its safety experience may not reflect patients whose illness is less stable. A TD treatment discussion should include harms that could undermine the very activities the patient hopes to regain.

Choosing among treatments is therefore more than choosing the agent most likely to lower a movement rating. It requires an explicit goal and a way to revisit whether the overall tradeoff is acceptable.

At follow-up, return to the activity the patient identified. Has it become easier? Is the patient doing it more often? Have adverse effects introduced another obstacle? Keep those answers alongside the movement examination rather than translating all progress into one total.

This is an editorial application of the guideline and consensus recommendations, not evidence that a particular treatment will restore employment, relationships or social confidence. A reduction in observed movements should not be reported as proof of those outcomes.

Monitoring can be a reasoned choice, including when the patient prefers it. But “mild” is not a sufficient explanation for that choice until its meaning has been tested against the person's experience. The useful endpoint of the conversation is an agreed treatment goal, or an explicit reason to observe, that takes the burden seriously.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. This article is not a diagnostic instrument or medication regimen. Patients should not change medication on the basis of this article.